Table 2.
Parametera | Placebo (n= 20) | Tolvaptan (n= 19) | P* |
---|---|---|---|
Serum Na (mEq/L) | 141±2 | 142±3 | 0.005 |
Serum K (mEq/L) | 4.1±0.5 | 4.0±0.5 | 0.34 |
Serum Cl (mEq/L) | 102±3 | 102±3 | 0.33 |
Serum Bicarb (mEq/L) | 28±3 | 27±3 | 0.29 |
Serum BUN (mg/dL) | 15±4 | 14±5 | 0.27 |
Serum Cr (mg/dL) | 0.9±0.2 | 0.9±0.2 | 0.21 |
Urine volume (ml/24h) | 1833±900 | 4794±2866 | <0.001 |
Urine pH | 6.3±0.6 | 6.5±0.4 | 0.34 |
Osmolarity, mOsm/kg | 529±213 | 204±96 | <0.001 |
Ammonia (mmol/24h) | 33±38 | 26±15 | 0.93 |
Calcium (mg/24h) | 148±106 | 106±55 | 0.25 |
Chloride (mmol/24h) | 108±72 | 91±44 | 0.39 |
Citrate (mg/24h) | 413±267 | 391±209 | 0.73 |
Creatinine (mg/24h) | 1096±1088 | 838±321 | 0.80 |
Magnesium (mg/spec) | 76±53 | 87±42 | 0.26 |
Oxalate (mg/24h) | 15±8 | 23±8 | 0.009 |
Phosphate (mg/24h) | 714±814 | 560±306 | 0.77 |
Potassium (mmol/24h) | 46±46 | 51±31 | 0.28 |
Sodium (mmol/24h) | 111±56 | 97±55 | 0.35 |
Uric acid (mg/24h) | 473±372 | 384±218 | 0.47 |
Calcium oxalate SS (DG) | 0.95±0.87 | −0.01±1.14 | <0.001 |
Calcium phosphate (BR) SS (DG) | −0.13±1.02 | −1.66±1.17 | <0.001 |
Uric acid SS (DG) | −2.05±4.05 | −5.24±3.12 | 0.04 |
Abbreviations: DG, delta Gibbs; SS, supersaturation.
All values presented as mean±s.d., unless otherwise specified.
P values were analyzed using wilcoxon matched-pairs signed-ranks tests in 19 patients who completed crossover study.